Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: December 2006
-
By Jason Derry — Merck & Co., Inc. has begun the process of moving a compound discovered in an effort with partner Isis Pharmaceuticals, Inc. toward clinical trials. The compound was discovered as part of a collaborative agreement between Merck and Isis, in which Merck relied on Isis' familiarity with technology relating to nucleic…
-
By Jason Derry — Affymetrix Inc. and Baylor College of Medicine have entered into an agreement in which Baylor receives a non-exclusive, worldwide license to use Affymetrix's comparative genomic hybridization (CGH) microarrays. Baylor intends to use the microarrays in services provided in Clinical Laboratory Improvement Amendments (CLIA) environments. The Press Release providing this news…
-
By Donald Zuhn — Opponents of gene patenting are once again speaking out against U.S. Patent Laws that permit applicants to secure patents on human genes. In a recent Parade.com article, Chicago-Kent College of Professor of Law, and longtime gene patent critic, Lori Andrews (at right) joined Michael Critchton, author of the recently…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma patent cases. A few interesting cases will be selected for periodic monitoring, providing our readers with an opportunity to follow the progress of these cases. We have no recently filed biotech or pharma cases…
-
By Donald Zuhn — In an appeal from a District Court judgment holding claims 1-5 of U.S. Patent No. 5,527,814 (the '814 patent) enforceable, valid, and infringed, the Federal Circuit affirmed the District Court's finding of no inequitable conduct, vacated the District Court's finding that claims 1-5 of the '814 patent were not invalid…
-
Communications to Swiss Patent Agents Held Not Subject to Privilege By Robert Dailey — A discovery order in the ongoing ANDA litigation over Exelon (In re Rivastigimine, No. 05-MD-1661-HB, S.D.N.Y.) held that attorney-client privilege does not attach to communications between Novartis and its Swiss patent agent. Communications to foreign patent agents are covered by…
-
By Mark Chael — On November 24, 2006, the Board of Patent Appeals and Interferences (BPAI) at the U.S. Patent and Trademark Office affirmed the examiner's rejection of the pending claims in U.S. Patent App. No. 10/305,577 (U.S. Patent App. Publication No. 2004/0101613) based on obviousness. The invention disclosed in the application relates…
Patent Docs 